IDSA Releases Guidance On Treatment Of Antimicrobial-Resistant Infections

  09 September 2020

Developed by a panel of six infectious diseases specialists with clinical and research expertise in the treatment of AMR bacterial infections, this first-in-a-series guidance addresses three groups of AMR Gram-negative bacteria that pose particular therapeutic challenges and have been designated as urgent or serious threats by CDC:

  • Extended-spectrum β-lactamase producing Enterobacterales (ESBL-E)
  • Carbapenem-resistant Enterobacterales (CRE)
  • Difficult-to-treat resistance (DTR)-Pseudomonas aeruginosa
Further reading: IDSA
Author(s): IDSA
Effective Surveillance   Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition





Technology Database

Display your AMR Technology, Product and Service

 

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

 

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!